Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT

Contemporary Clinical Trials

Volumn 32, Issue 2, 2011, Pages 280-287

  Kawut, Steven M ^a   Bagiella, Emilia ^b   Shimbo, Daichi ^c   Lederer, David J ^c   Al Naamani, Nadine ^c   Roberts, Kari E ^d   Barr, R Graham ^b,c   Post, Wendy ^e   Horn, Evelyn M ^f   Tracy, Russell ^g   Hassoun, Paul ^e   Girgis, Reda ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Mailman School of Public Health   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Endothelial dysfunction; Platelets; Pulmonary hypertension

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; SIMVASTATIN; TINY TABLETS; UNCLASSIFIED DRUG;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; WALKING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; P-SELECTIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME;

EID: 79551554855     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.12.005     Document Type: Article

References (17)

1. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70-75.
2. Robbins I.M., Kawut S.M., Yung D., et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006, 27:578-584.
3. Stuard I.D., Heusinkveld R.S., Moss A.J. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med 1972, 287:869-870.
4. Suzuki H., Nakasato M., Sato S., et al. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J Exp Med 1997, 181:379-384.
5. Chin K.M., Channick R.N., de Lemos J.A., et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009, 135:130-136.
6. Bowers R., Cool C., Murphy R.C., et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004, 169:764-769.
7. Mittal M., Roth M., Konig P., et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007, 101:258-267.
8. Girgis R.E., Mozammel S., Champion H.C., et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1105-L1110.
9. Nishimura T., Vaszar L.T., Faul J.L., et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003, 108:1640-1645.
10. Wilkins M.R., Ali O., Bradlow W., et al. Simvastatin as a treatment for pulmonary hypertension trial (SiPHT). Am J Respir Crit Care Med 2010, 181:1106-1113.
11. Katz S.D., Hryniewicz K., Hriljac I., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111:310-314.
12. Yeboah J., Folsom A.R., Burke G.L., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
13. Fathi R., Haluska B., Short L., et al. A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention. Am J Med 2003, 114:445-453.
14. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191-196.
15. Sakamaki F., Kyotani S., Nagaya N., et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000, 102:2720-2725.
16. Fleiss J.L. The design and analysis of clinical experiments 1986, Wiley, New York.
17. Cook T.D., DeMets D.L. Introduction to statistical methods for clinical trials 2008, Chapman & Hall.